-
公开(公告)号：EP3793592A1
公开(公告)日：2021-03-24
申请号：EP19717884.1
申请日：2019-04-12
-
22.发明公开
公开(公告)号：EP3760225A2
公开(公告)日：2021-01-06
申请号：EP20179381.7
申请日：2016-04-22
发明人： MAHR, Andrea , WEINSCHENK, Toni , SCHOOR, Oliver , FRITSCHE, Jens , SINGH, Harpreet , WAGNER, Claudia , LEIBOLD, Julia , SONG, Colette
摘要： The present invention relates to peptides, especially the peptide of SEQ ID Nos. 24, 26 and 159, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor- associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
23.发明公开
公开(公告)号：EP3712165A3
公开(公告)日：2020-12-02
申请号：EP20170129.9
申请日：2016-06-29
发明人： MAHR, Andrea , WEINSCHENK, Toni , HÖRZER, Helen , SCHOOR, Oliver , FRITSCHE, Jens , SINGH, Harpreet
摘要： Provided is a peptide of up to 30 amino acids comprising the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 1 or SEQ ID NO: 2, or one of SEQ ID NO: 4 to SEQ ID NO: 10 or SEQ ID NO: 12 to SEQ ID NO: 640. Provided are inter alia also a nucleic acid encoding such peptide, a host cell comprising the same, a T-cell receptor reactive with such peptide and an activated T lymphocyte recognizing a cell which presents such peptide. Provided is also the use of any of the above in cancer treatment.
-
公开(公告)号：EP3120869B1
公开(公告)日：2020-07-22
申请号：EP16179192.6
申请日：2009-09-28
-
25.发明公开
公开(公告)号：EP3626730A1
公开(公告)日：2020-03-25
申请号：EP19199106.6
申请日：2015-12-16
发明人： WEINSCHENK, Toni , MAHR, Andrea , FRITSCHE, Jens , MÜLLER, Phillip , WIEBE, Anita , MISSEL, Sarah
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically / immunologically active compounds and cells.
-
公开(公告)号：EP3616712A1
公开(公告)日：2020-03-04
申请号：EP19202064.2
申请日：2014-08-04
IPC分类号： A61K38/17 , A61K39/00 , C07K7/06 , C12N5/0783
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to more than 70 novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：EP3616711A1
公开(公告)日：2020-03-04
申请号：EP19202056.8
申请日：2014-08-04
IPC分类号： A61K38/17 , A61K39/00 , C07K7/06 , C12N5/0783
摘要： The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to more than 70 novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：EP3030255B1
公开(公告)日：2019-10-09
申请号：EP14750175.3
申请日：2014-08-04
IPC分类号： A61K38/17 , A61K39/00 , C07K7/06 , C12N5/0783 , C07K7/08
-
29.发明公开
公开(公告)号：EP3504228A1
公开(公告)日：2019-07-03
申请号：EP17758503.1
申请日：2017-08-24
发明人： MAHR, Andrea , WEINSCHENK, Toni , WIEBE, Anita , SONG, Colette , SCHOOR, Oliver , FRITSCHE, Jens , SINGH, Harpreet
IPC分类号： C07K14/47
-
30.发明公开
公开(公告)号：EP3461494A1
公开(公告)日：2019-04-03
申请号：EP18201208.8
申请日：2016-08-26
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
搜索结果
125 条记录 (耗时 0.064 秒)
